First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate

The high cost of tyrosine kinase inhibitors (TKIs) developed for chronic myeloid leukaemia (CML) is a major concern for healthcare payers, especially in countries with restricted resources. Reimbursement policies encourage generic drug use to lower the prices. It is true that generics lead to considerable cost savings but they also give rise to questions associated with their efficacy, safety and quality (Experts in Chronic Myeloid Leukemia,...